A novel Fc silencing technology developed at Absolute Antibody has been formally spun-out into a new business entity – mAbsolve Limited. Prof. Geoff Hale becomes CEO of mAbsolve with Dr. Ian Wilkinson and Dr. Nicholas Hutchings as non-executive directors. mAbsolve will further develop the Fc silencing technology with the ultimate intention of licensing it to developers of therapeutic antibodies.

Posted in